• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Bio Green Med Solution, Inc. Announces Closing of Strategic Acquisition of Fitters Sdn. Bhd.

    9/12/25 6:00:00 AM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CYCC alert in real time by email

    KUALA LUMPUR, Malaysia, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ:BGMS, NASDAQ:BGMSP) ("Bio Green Med" or the "Company"), a company engaged in diversified industries, today announced that it has closed the previously announced transaction (the "Exchange Transaction") to acquire Fitters Sdn. Bhd. ("Fitters"), a Malaysia private limited company and wholly-owned subsidiary of FITTERS Diversified Berhad, a Malaysian publicly listed company ("Fitters Parent"). Following the closing of the Exchange Transaction, which was approved by the Company's stockholders during a Special Meeting that took place on September 4, 2025, Fitters became a wholly-owned subsidiary of the Company and Datuk Dr. Doris Wong Sing Ee, our Chief Executive Officer and Executive Director was appointed to the board of directors of Fitters and all of its subsidiaries.

    Fitters specializes in the supply and trading of protective and fire safety equipment. It is headquartered in Kuala Lumpur, Malaysia, and provides a wide range of fire safety products, including fire extinguishers, foam system, fire-resistant doors, personal protective equipment, and fire safety apparel. Fitters' mission is to deliver high-quality, certified safety solutions that enhance protection across commercial, industrial, healthcare, and residential sectors. Its focus on trading and distribution positions it as a key player in Malaysia's fire safety market, with a reputation for reliability and compliance with stringent regulatory standards. Over the past four decades, Fitters has expanded its product portfolio to include advanced fire-fighting equipment, foam system, personal protective equipment, and safety apparel, establishing a strong presence in the industry.

    Through the Exchange Transaction, the Company has diversified its business portfolio by adding fire protection and safety products and services to its ongoing business interests in the pharmaceutical sector. As a result of the Exchange Transaction, the Company changed the ticker symbols for its common stock and preferred stock from CYCC and CYCCP, respectively, to BGMS and BGMSP, respectively. The Company's securities will continue to trade on the Nasdaq. No action is required by the Company's stockholders with respect to the ticker symbol change. The Company's CUSIP numbers, the unique identifier for the security, will remain unchanged.

    "We are pleased to complete this transaction, which diversifies our business and represents an important milestone in our corporate development," said Datuk Dr. Doris Wong, Chief Executive Officer of Bio Green Med. "By integrating Fitters' established operations while continuing to maintain our presence in pharmaceuticals, the Company is positioned to explore opportunities across multiple industries and create long-term value for shareholders."

    Transaction Details

    Pursuant to the previously announced share exchange agreement (the "Exchange Agreement"), among the Company, Fitters and Fitters Parent, at closing the Company issued 699,158 shares of its common stock to FITTERS Diversified Berhad equal to 19.99% of the issued and outstanding shares of the Company's common stock, in exchange for all of the issued and outstanding equity interests of Fitters. As a result of the Exchange Transaction, Fitters became a wholly owned subsidiary of the Company. The exchange consideration was determined in accordance with the Exchange Agreement and as disclosed in the Company's filings with the U.S. Securities and Exchange Commission (the "SEC").

    About Bio Green Med Solution, Inc.

    Bio Green Med Solution, Inc. (formerly Cyclacel Pharmaceuticals, Inc.) is a diversified company engaged in both the fire protection and biopharmaceutical industries. Building on its legacy in pharmaceutical research and development, the Company has expanded its business portfolio through the integration of Fitters Sdn. Bhd., a Malaysia-based group specializing in fire protection products and services. Headquartered in Malaysia, Bio Green Med Solution, Inc. is focused on advancing opportunities across these distinct sectors while maintaining its commitment to driving long-term value creation for shareholders. For additional information, visit www.bgmsglobal.com.

    About Fitters Sdn. Bhd.

    Fitters specializes in distributing, trading and installing various protective and fire safety materials and equipment and fire protection and prevention systems with a reputation for reliability and compliance with stringent regulatory standards.

    • Operates as a "ONE-STOP" Protective Clothing Specialist and distribution of fire retardant uniforms and supplier of Scotchlite reflective material.
    • Headquartered in Kuala Lumpur, Malaysia, Fitters provides a wide range of fire safety products, including fire extinguishers, foam system, fire-resistant doors, personal protective equipment (PPE), and fire safety apparel.
    • Mission is to deliver high-quality, certified safety solutions that enhance protection across commercial, industrial, healthcare, and residential sectors.



    Financial and Legal Advisors to the Transaction

    ARC Group Limited is acting as exclusive financial advisor to Bio Green Med with Rimon, P.C. (Washington, DC) serving as Bio Green Med's legal counsel. Messrs. Ong, Ric & Partners, Advocates & Solicitors (Kuala Lumpur) is serving as legal counsel to Fitters Parent and Fitters.

    Forward-Looking Statement

    Certain statements contained in this press release may be considered forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding its diversification into the fire protection and safety sector, the integration and future performance of Fitters and the Company's ongoing business interests in the pharmaceutical sector. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "anticipate," "plan," "likely," "believe," "estimate," "project," "intend," and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance.

    Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: (i) the ability of the Company and Fitters to integrate their businesses successfully and to achieve anticipated synergies; (ii) the possibility that other anticipated benefits of the transaction will not be realized, including without limitation, anticipated revenues, expenses, earnings and other financial results, and growth and expansion of the combined company's operations, and the anticipated tax treatment of the combination; (iii) potential litigation relating to the proposed transaction that could be instituted against the Company, Fitters, Fitters Parent or their respective directors; (iv) the ability of the Company and Fitters to retain, attract and hire key personnel; (v) potential adverse reactions or changes to relationships with customers, employees, suppliers or other parties resulting from the completion of the transaction; (vi) potential business uncertainty, including changes to existing business relationships, during the integration of Fitters that could affect the Company's or Fitters' financial performance; (vii) certain restrictions during the integration of Fitters that may impact the Company's or Fitters' ability to pursue certain business opportunities or strategic transactions; (viii) legislative, regulatory and economic developments; (ix) unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak of war or hostilities, as well as management's response to any of the aforementioned factors; and (x) such other factors as are set forth in the Company's periodic public filings with the SEC, including but not limited to those described under the heading "Risk Factors" in the Company's Form 10-K for the fiscal year ended December 31, 2024.

    New risks and uncertainties emerge from time to time, and it is not possible for our management to predict all risks and uncertainties, nor can management assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. Neither we nor any other person assumes responsibility for the accuracy or completeness of any of these forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

    For more information, please contact:

    Bio Green Med Solution, Inc.

    Datuk Dr. Doris Wong

    Chief Executive Officer

    Email: [email protected]



    Get the next $CYCC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CYCC

    DatePrice TargetRatingAnalyst
    7/18/2022$17.00Outperform
    Oppenheimer
    More analyst ratings

    $CYCC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer resumed coverage on Cyclacel Pharma with a new price target

    Oppenheimer resumed coverage of Cyclacel Pharma with a rating of Outperform and set a new price target of $17.00

    7/18/22 9:13:15 AM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Cyclacel Pharmaceuticals with a new price target

    Oppenheimer initiated coverage of Cyclacel Pharmaceuticals with a rating of Outperform and set a new price target of $17.00

    4/30/21 6:36:41 AM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYCC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bio Green Med Solution, Inc. Announces Closing of Strategic Acquisition of Fitters Sdn. Bhd.

    KUALA LUMPUR, Malaysia, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ:BGMS, NASDAQ:BGMSP) ("Bio Green Med" or the "Company"), a company engaged in diversified industries, today announced that it has closed the previously announced transaction (the "Exchange Transaction") to acquire Fitters Sdn. Bhd. ("Fitters"), a Malaysia private limited company and wholly-owned subsidiary of FITTERS Diversified Berhad, a Malaysian publicly listed company ("Fitters Parent"). Following the closing of the Exchange Transaction, which was approved by the Company's stockholders during a Special Meeting that took place on September 4, 2025, Fitters became a wholly-owned subsidiary of t

    9/12/25 6:00:00 AM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update

    KUALA LUMPUR, Malaysia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative medicines, today announced its second quarter financial results and provided a business update. Highlights of the second quarter ended June 30, 2025, or in some cases shortly thereafter, include: In April, the Company announced that the Board of Directors of the Company declared a quarterly cash dividend of $0.15 per share on the Company's 6% Convertible Exchangeable Preferred Stock, which cash dividend was paid on May 1, 2025, to holders of 6% Convertible Exchangeable P

    8/13/25 4:05:00 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB

             - Biliary tract cancer (BTC) or cholangiocarcinoma is an aggressive tumor with poor prognosis - KUALA LUMPUR, Malaysia, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative cancer medicines, highlighted a preclinical study from independent investigators titled, "Evaluation of antitumor effects of plogosertib, PLK1 inhibitor in biliary tract cancer with BUBR1 as a potential biomarker" in the journal, Cancer Research, previously reported in a poster at the American Association of Cancer Research 2025 annual meeting.1 The investigators found that several BT

    8/4/25 6:50:00 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYCC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Fitters Diversified Berhad claimed ownership of 699,158 shares (SEC Form 3)

    3 - Bio Green Med Solution, Inc. (0001130166) (Issuer)

    9/16/25 3:31:42 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Kua Khai Loon sold $133,569 worth of shares (19,054 units at $7.01), decreasing direct ownership by 5% to 385,411 units (SEC Form 4)

    4 - Cyclacel Pharmaceuticals, Inc. (0001130166) (Issuer)

    9/10/25 3:09:51 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Ong Yee Lung acquired 186,465 shares, increasing direct ownership by 86% to 404,465 units (SEC Form 4)

    4 - Cyclacel Pharmaceuticals, Inc. (0001130166) (Issuer)

    9/4/25 4:00:15 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYCC
    SEC Filings

    View All

    Cyclacel Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Bio Green Med Solution, Inc. (0001130166) (Filer)

    9/16/25 4:05:31 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 425 filed by Cyclacel Pharmaceuticals Inc.

    425 - Cyclacel Pharmaceuticals, Inc. (0001130166) (Subject)

    9/12/25 6:09:33 AM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cyclacel Pharmaceuticals Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Cyclacel Pharmaceuticals, Inc. (0001130166) (Filer)

    9/12/25 6:07:02 AM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYCC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Rombotis Spiro George bought $20,122 worth of shares (6,070 units at $3.31), increasing direct ownership by 10% to 68,658 units (SEC Form 4)

    4 - Cyclacel Pharmaceuticals, Inc. (0001130166) (Issuer)

    12/26/23 4:05:23 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mcbarron Paul bought $6,252 worth of shares (1,886 units at $3.31), increasing direct ownership by 6% to 33,378 units (SEC Form 4)

    4 - Cyclacel Pharmaceuticals, Inc. (0001130166) (Issuer)

    12/26/23 4:05:25 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYCC
    Leadership Updates

    Live Leadership Updates

    View All

    Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update

    BERKELEY HEIGHTS, N.J., April 02, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, "Cyclacel" or the "Company")), a biopharmaceutical company developing innovative medicines, today announced fourth quarter financial results and provided a business update. "As part of Cyclacel's efforts to reduce operating costs, it has determined to focus on the development of plogosertib, a polo-like kinase 1 (PLK 1) inhibitor for treatment of advanced cancers and hematological malignancies, which we acquired on March 10, 2025, from Cyclacel Limited, our wholly-owned subsidiary that is currently in liquidation," said Datuk Dr. Doris Wong Sing Ee, Chief Executive Officer

    4/2/25 4:05:00 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer

    BERKELEY HEIGHTS, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", ))), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that Brian Schwartz, M.D. will assume the role of interim Chief Medical Officer ("CMO") of the Company effective immediately. Dr. Schwartz will succeed Mark Kirschbaum, M.D., whose employment was terminated by the Company. "We are delighted to have Brian join Cyclacel as CMO. His extensive clinical and product development experience in oncology and hematology further adds to the strengths of our team and will support our efforts

    1/30/24 9:15:00 AM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cyclacel Pharmaceuticals Reviews 2020 Achievements and Announces Key Business Objectives for 2021

    – Anticancer Activity of Fadraciclib Monotherapy in Patients with MCL1 Amplified Solid Tumors–– Appointment of Mark Kirschbaum, M.D. as Chief Medical Officer –– $7 Million Strategic Investment by Fundamental Investor Acorn Bioventures– BERKELEY HEIGHTS, N.J., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today provided a business update reviewing 2020 achievements and outlining the Company’s key business objectives for 2021. The Company will present at Biotech Showcase™ Digital 2021 taking place virtually from Januar

    1/11/21 7:46:19 AM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYCC
    Financials

    Live finance-specific insights

    View All

    Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update

    KUALA LUMPUR, Malaysia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative medicines, today announced its second quarter financial results and provided a business update. Highlights of the second quarter ended June 30, 2025, or in some cases shortly thereafter, include: In April, the Company announced that the Board of Directors of the Company declared a quarterly cash dividend of $0.15 per share on the Company's 6% Convertible Exchangeable Preferred Stock, which cash dividend was paid on May 1, 2025, to holders of 6% Convertible Exchangeable P

    8/13/25 4:05:00 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

    KUALA LUMPUR, MALAYSIA, May 15, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative medicines, today announced its first quarter financial results and provided a business update. "As part of the Company's efforts to reduce operating costs it has determined to focus on the development of the plogosertib ("plogo") clinical program only. Accordingly, on March 10, 2025, the Company repurchased certain assets related to plogo from Cyclacel Limited for approximately $0.3 million in cash, to allow us to continue our efforts on developing an alternative salt, oral formulation of

    5/15/25 12:50:00 AM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

    BERKELEY HEIGHTS, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative medicines, today announced third quarter financial results and provided a business update. "We were pleased to report initial safety and efficacy data from twelve patients with advanced solid tumors enrolled in the Phase 2 part of the 065-101, proof of concept, clinical study of fadraciclib as a single agent as a poster presentation at the 2024 EORTC-NCI-AACR 36th Symposium on Molecular Targets and Cancer Therapeutics ("Triple Meeting"), in Barcelona, Spain. The patients were enrolled in

    11/12/24 4:45:00 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYCC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cyclacel Pharmaceuticals Inc.

    SC 13G/A - Cyclacel Pharmaceuticals, Inc. (0001130166) (Subject)

    11/14/24 7:21:58 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Cyclacel Pharmaceuticals Inc.

    SC 13G - Cyclacel Pharmaceuticals, Inc. (0001130166) (Subject)

    11/14/24 3:27:04 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Cyclacel Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Cyclacel Pharmaceuticals, Inc. (0001130166) (Subject)

    2/14/24 4:31:09 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care